Time For Independent FDA? COVID-19 Political Pressure Reignites Debate
Executive Summary
The political spotlight on the Food & Drug Administration during the COVID-19 pandemic has renewed the long-standing debate as to whether FDA should be made an independent, Cabinet-level federal agency and freed from direct HHS oversight.
You may also be interested in...
Politics Is US FDA Commissioners’ Biggest Challenge, Ex-Trump Agency Head Hahn Says
In a Pink Sheet interview, Stephen Hahn also discusses the unique risk-benefit calculations that may come into play for the ‘preemptive’ therapeutics he hopes to spearhead in his new position at Flagship Pioneering and his tendency to follow in the career path of another former commissioner, Scott Gottlieb.
Politics Is US FDA Commissioners’ Biggest Challenge, Ex-Trump Agency Head Hahn Says
In a Pink Sheet interview, Stephen Hahn also discusses the unique risk-benefit calculations that may come into play for the ‘preemptive’ therapeutics he hopes to spearhead in his new position at Flagship Pioneering and his tendency to follow in the career path of another former commissioner, Scott Gottlieb.
Pandemic Perspectives: How COVID Emergency Use Authorizations Could Reshape US FDA
From re-examining the FDA’s place in the broader US government to how fast and flexible it can be clearing therapies in non-emergency times, the COVID-19 EUA experience is expected to have a long-lasting impact on the agency.